Business
GenSight Biologics Announces Successful Fundraising Amounting to Nearly €2.9 Million
PARIS, December 29, 2025--Regulatory News: NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA
About this update from Gensight Biologics Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":204,"url":"https://media.zenfs.com/en/business-wire.com/0cf9f8c3bf32b70af184e588ed0e4d9c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/h2E0y06ltgK0sbRDLYbUsg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQwODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/0cf9f8c3bf32b70af184e588ed0e4d9c","width":480,"height":204}},"lazy":false},{"type":"text","content":"PARIS, December 29, 2025--(BUSINESS WIRE)--Regulatory News:","length":59,"tagName":"p"},{"type":"text","content":"NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA","length":120,"tagName":"p","attribs":{}},{"type":"text","content":"GenSight Biologics ("GenSight" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the successful completion of a EUR 2,894,715.96 fundraising subscribed by three of its shareholders: Heights Capital, Invus and Alumni Capital (the "Fundraising"). This fundraising follows the EUR 4.5 million private placement completed in July (in two tranches), the EUR 3.7 million fundraising completed in early October and the EUR 2 million fundraising completed in November. The Fundraising uses the same structure of shares and warrants, including pre-funded warrants, as detailed further below.","length":818,"tagName":"p"},{"type":"text","content":""2025 has been a transformative year for GenSight Biologics. Securing compassionate use approvals in three major markets—the United States, France, and Israel—represent a significant regulatory milestone," said Laurence Rodriguez, Chief Executive Officer of GenSight Biologics. "These achievements, soon to be capped with the completion of our manufacturing technology transfer in December 2025, give us tremendous momentum to take into the coming year. I want to extend my deepest gratitude to our shareholders for their steadfast support throughout 2025 and in this latest financing round. Their commitment enables us to execute our vision, and we look forward to passin...